248 related articles for article (PubMed ID: 26285571)
1. Histological criteria for atypical pituitary adenomas - data from the German pituitary adenoma registry suggests modifications.
Miermeister CP; Petersenn S; Buchfelder M; Fahlbusch R; Lüdecke DK; Hölsken A; Bergmann M; Knappe HU; Hans VH; Flitsch J; Saeger W; Buslei R
Acta Neuropathol Commun; 2015 Aug; 3():50. PubMed ID: 26285571
[TBL] [Abstract][Full Text] [Related]
2. The Prognostic Roles of the Ki-67 Proliferation Index, P53 Expression, Mitotic Index, and Radiological Tumor Invasion in Pituitary Adenomas.
Hasanov R; Aydoğan Bİ; Kiremitçi S; Erden E; Güllü S
Endocr Pathol; 2019 Mar; 30(1):49-55. PubMed ID: 30610566
[TBL] [Abstract][Full Text] [Related]
3. Ki-67 labeling index and expression of p53 are non-predictive for invasiveness and tumor size in functional and nonfunctional pituitary adenomas.
Grimm F; Maurus R; Beschorner R; Naros G; Stanojevic M; Gugel I; Giese S; Bier G; Bender B; Honegger J
Acta Neurochir (Wien); 2019 Jun; 161(6):1149-1156. PubMed ID: 31037500
[TBL] [Abstract][Full Text] [Related]
4. Atypical pituitary adenomas: clinical characteristics and role of ki-67 and p53 in prognostic and therapeutic evaluation. A series of 50 patients.
Del Basso De Caro M; Solari D; Pagliuca F; Villa A; Guadagno E; Cavallo LM; Colao A; Pettinato G; Cappabianca P
Neurosurg Rev; 2017 Jan; 40(1):105-114. PubMed ID: 27215912
[TBL] [Abstract][Full Text] [Related]
5. A classification tree approach for pituitary adenomas.
Righi A; Agati P; Sisto A; Frank G; Faustini-Fustini M; Agati R; Mazzatenta D; Farnedi A; Menetti F; Marucci G; Foschini MP
Hum Pathol; 2012 Oct; 43(10):1627-37. PubMed ID: 22446019
[TBL] [Abstract][Full Text] [Related]
6. Low aryl hydrocarbon receptor-interacting protein expression is a better marker of invasiveness in somatotropinomas than Ki-67 and p53.
Kasuki Jomori de Pinho L; Vieira Neto L; Armondi Wildemberg LE; Gasparetto EL; Marcondes J; de Almeida Nunes B; Takiya CM; Gadelha MR
Neuroendocrinology; 2011; 94(1):39-48. PubMed ID: 21178332
[TBL] [Abstract][Full Text] [Related]
7. Typical and atypical pituitary adenomas: a single-center analysis of outcome and prognosis.
Chiloiro S; Doglietto F; Trapasso B; Iacovazzo D; Giampietro A; Di Nardo F; de Waure C; Lauriola L; Mangiola A; Anile C; Maira G; De Marinis L; Bianchi A
Neuroendocrinology; 2015; 101(2):143-50. PubMed ID: 25633744
[TBL] [Abstract][Full Text] [Related]
8. Atypical pituitary adenoma: a clinicopathologic case series.
Rutkowski MJ; Alward RM; Chen R; Wagner J; Jahangiri A; Southwell DG; Kunwar S; Blevins L; Lee H; Aghi MK
J Neurosurg; 2018 Apr; 128(4):1058-1065. PubMed ID: 28598278
[TBL] [Abstract][Full Text] [Related]
9. Implications of the World Health Organization definition of atypia on surgically treated functional and non-functional pituitary adenomas.
Sarkar S; Philip VJ; Cherukuri SK; Chacko AG; Chacko G
Acta Neurochir (Wien); 2017 Nov; 159(11):2179-2186. PubMed ID: 28573325
[TBL] [Abstract][Full Text] [Related]
10. Atypical pituitary adenomas: incidence, clinical characteristics, and implications.
Zada G; Woodmansee WW; Ramkissoon S; Amadio J; Nose V; Laws ER
J Neurosurg; 2011 Feb; 114(2):336-44. PubMed ID: 20868211
[TBL] [Abstract][Full Text] [Related]
11. DNA mismatch repair protein (MSH6) correlated with the responses of atypical pituitary adenomas and pituitary carcinomas to temozolomide: the national cooperative study by the Japan Society for Hypothalamic and Pituitary Tumors.
Hirohata T; Asano K; Ogawa Y; Takano S; Amano K; Isozaki O; Iwai Y; Sakata K; Fukuhara N; Nishioka H; Yamada S; Fujio S; Arita K; Takano K; Tominaga A; Hizuka N; Ikeda H; Osamura RY; Tahara S; Ishii Y; Kawamata T; Shimatsu A; Teramoto A; Matsuno A
J Clin Endocrinol Metab; 2013 Mar; 98(3):1130-6. PubMed ID: 23365123
[TBL] [Abstract][Full Text] [Related]
12. Ki-67 expression for predicting progression of postoperative residual pituitary adenomas: correlations with clinical variables.
Matsuyama J
Neurol Med Chir (Tokyo); 2012; 52(8):563-9. PubMed ID: 22976139
[TBL] [Abstract][Full Text] [Related]
13. Labeling index in pituitary adenomas evaluated by means of MIB-1: is there a prognostic role? A critical review.
de Aguiar PH; Aires R; Laws ER; Isolan GR; Logullo A; Patil C; Katznelson L
Neurol Res; 2010 Dec; 32(10):1060-71. PubMed ID: 20483025
[TBL] [Abstract][Full Text] [Related]
14. Clinicopathological study of prognostic factors in patients with pituitary adenomas and Ki-67 labeling index of more than 3%.
Ogawa Y; Ikeda H; Tominaga T
J Endocrinol Invest; 2009 Jul; 32(7):581-4. PubMed ID: 19509474
[TBL] [Abstract][Full Text] [Related]
15. Minichromosome maintenance protein 7 as prognostic marker of tumor aggressiveness in pituitary adenoma patients.
Coli A; Asa SL; Fadda G; Scannone D; Chiloiro S; De Marinis L; Lauretti L; Ranelletti FO; Lauriola L
Eur J Endocrinol; 2016 Mar; 174(3):307-14. PubMed ID: 26620390
[TBL] [Abstract][Full Text] [Related]
16. Cystic versus non-cystic silent corticotrophic adenomas: clinical and histological analysis of 62 cases after microscopic transsphenoidal surgery-a retrospective, single-center study.
Sumislawski P; Huckhagel T; Krajewski KL; Aberle J; Saeger W; Flitsch J; Rotermund R
Sci Rep; 2023 Feb; 13(1):2468. PubMed ID: 36774403
[TBL] [Abstract][Full Text] [Related]
17. [Non-functioning pituitary adenomas: clinical features and immunohistochemistry].
Ferreira JE; de Mello PA; de Magalhães AV; Botelho CH; Naves LA; Nosé V; Schmitt F
Arq Neuropsiquiatr; 2005 Dec; 63(4):1070-8. PubMed ID: 16400431
[TBL] [Abstract][Full Text] [Related]
18. Pituitary macroadenomas (>3 cm) in young adulthood: Pathologic and proliferative characteristics.
Öngürü Ö; Düz B; Şimşek H; Günal A; Gönül E
Neurol Neurochir Pol; 2015; 49(4):212-6. PubMed ID: 26188936
[TBL] [Abstract][Full Text] [Related]
19. Recurrences of Pituitary Adenomas or Second De Novo Tumors: Comparisons with First Tumors.
Saeger W; Müller M; Buslei R; Flitsch J; Fahlbusch R; Buchfelder M; Knappe UJ; Crock PA; Lüdecke DK
World Neurosurg; 2018 Nov; 119():e118-e124. PubMed ID: 30026158
[TBL] [Abstract][Full Text] [Related]
20. Role of Ki-67 proliferation index and p53 expression in predicting progression of pituitary adenomas.
Gejman R; Swearingen B; Hedley-Whyte ET
Hum Pathol; 2008 May; 39(5):758-66. PubMed ID: 18439942
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
